B-lymphocyte-targeted therapy for systemic lupus erythematosus

( views:406, downloads:0 )
Author:
WANG Chang-sheng(Department of Nephrology and Rheumatology,First Affiliated Hospital of Zunyi Medical College,Zunyi 563003,Guizhou,China)
YANG Yi-bin(Department of Nephrology and Rheumatology,First Affiliated Hospital of Zunyi Medical College,Zunyi 563003,Guizhou,China)
Journal Title:
INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY
Issue:
Volume 35, Issue 02, 2009
DOI:
10.3760/cma.j.issn.1673-4173.2009.02.011
Key Word:
Lupus erythematosus,systemic;B-lymphocyte;Therapy

Abstract: Treatment of SLE is versatile.B-lymphocyte-targeted therapy is a new clinical approach which has not been generally applied in China.International studies have proved it to be highly effective,safe and tolerable.So.it shows a fine application prospect and is expected to offer a new treatment approach to patients with SLE,especially to those resistant to conventional therapy and those suffering from serious adverse side effects.The true efficacy and long-term side effects of this approach remain to be further evaluated via large-scale trials and long-term follow-up.

  • [1]Taylor RR,Carugati A,Fadok VA,et al.A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo.J Exp Med,2000,192(3):359-366.
  • [2]Scott RS,McMahon EJ,Pop SM,et al.Phagocytosis and clearance of apoptotic cells is mediated by MER.Nature,2001,411(6834):207-211.
  • [3]Carter RH.B cells in health and disease.Mayo Clin Proc,2006,81(3):377-384.
  • [4]Anolik JH,Campbell D,Felgar RE,et al.B lymphocyte depletion in the treatment of systemic lupus erythematosus.Arthritis Rheurm,2002,46(Suppl 9):S717.
  • [5]Leadro MJ,Edwards JC,Cambridge G,et al.An open study of B lymphocyte depletion in systemic lupus erythematosus.Arthritis Rheum,2002,46(10):2673-2677.
  • [6]Leandro MJ,Cambridge G,Edwards JC,et al.B-cell depletion in the treatment of patients with systemic lupus erythematosus:a longitudinal analysis of 24 patients.Rheumatology (Oxford),2005,44(12):1542-1545.
  • [7]Anolik JH,Barnard J,Cappione A,et al.Rituximab improves Peripheral B cell abnormalities in human systemic lupus erythematosus.Arthritis Rheum,2004,50(11):3580-3590.
  • [8]Tamimoto Y,Horiuchi T,Tsukamoto H,et al.A dose-escalation study of rimximab for treatment of systemic lupus erythematosus and Evans'syndrome:immunological analysis of B cells,T cells and cytokines.Rheumatology (Oxford),2008,47(6):821-827.
  • [9]Anolik JH,Campbell D,Felgar RE,et al.The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.Arthritis Rheum,2003,48(2):455-459.
  • [10]D(o)rner T,Kaufinann J,Wegener WA,et al.Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.Arthritis Res Ther,2006,8(3):R74.
  • [11]Furie R,Stohl W,Ginzler E,et al.Safety,pharmacokinetic and pharmacodynamic results of a phase Ⅰ single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BlyS) in SLE patients.Arthritis Rheum,2003,48(Suppl S):S377.
  • [12]Sabahi R,Anolik JH.B-cell-targeted therapy for systemic lupus erythematosus.Drugs,2006,66(15):1933-1948.
  • [13]Dall'Era M,Chakravarty E,Wallace D,et al.Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus:results of a multicenter,phase Ib,double-blind,placebo-controlled,dose-escalating trial.Arthritis Rhcam,2007,56(12):4142-4150.
  • [14]Alarcon-Segovia D,Tumlin JA,Furie RA,et al.LJP394 for the prevention of renal flare in patients with systemic lupus erythematosus:results from a randomized,double-blind,placebo-controlled study.Arthritis Rheum,2003,48(2):442-454.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn